Yuqi Tang

Ms. Yuqi Tang

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2026 in EBioMedicine
Verified
Journal Article
Open access
QWQi Wang
Qi Wang
FCFeng Chen
Feng Chen
YTYuqi Tang
Yuqi Tang
JZJuanjuan Zhang
Juanjuan Zhang
ZSZhengyu Sun
Zhengyu Sun
LLLiang Liu
Liang Liu
Live cell-based assay (LCBA) is the gold standard for sensitive detection of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) autoantibodies in neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody-associated disorder (MOGAD). However, LCBA is less practical, standardisable and cost-effective than fixed cell-based assay (FCBA). We developed a high-performance untransfected vector cells lysate, named AbFine, to process patients' sera to pre-bind and deplete interferents before FCBA, and examined its rationality. We then conducted a multicentre, double-blind, prospective discovery study to compare the diagnostic accuracy of conventional FCBA, FCBA-AbFine, and LCBA in detecting AQP4-IgG and MOG-IgG. A retrospective validation cohort was used to assess generalisability. Participants included patients with NMOSD, MOGAD, and seronegative inflammatory demyelination syndromes, and controls with other neurological disorders. 818 participants were recruited, including 410 in the discovery and 408 in the validation cohorts with good consistency. Among 205 patients with NMOSD, AQP4-IgG was detected in 165, 185, and 178 by FCBA, FCBA-AbFine, and LCBA, yielding sensitivity of 80.5% (95% CI, 74.4-85.7), 90.2% (95% CI, 85.3-93.9), and 86.8% (95% CI, 81.4-91.1), respectively. Among 171 patients with MOGAD, MOG-IgG was found in 134, 155, and 158 by FCBA, FCBA-AbFine, and LCBA, with sensitivity of 78.4% (95% CI, 71.4-84.3), 90.6% (95% CI, 85.3-94.6), and 92.4% (95% CI, 87.4-95.9), respectively. All assays achieved specificity greater than 99.5%. The area under the curve for FCBA-AbFine was higher than that for FCBA for both AQP4-IgG (0.950 vs. 0.902; p < 0.0001) and MOG-IgG (0.935 vs. 0.888; p < 0.05), and was comparable to LCBA (AQP4-IgG 0.950 vs. 0.934; MOG-IgG 0.935 vs. 0.940; p > 0.05 for both). AbFine enables the use of FCBA as an alternative to LCBA in AQP4-IgG and MOG-IgG detection with operationally practical and cost-efficient characteristics and could be extended to other fixed cellular assays. Beijing Precigen Biopharma Co., Ltd., Beijing, China.

18 August 2021 in Research Square
Verified
Preprint
Open access
PDF file
XLXinyu Liu
Xinyu Liu
YTYuqi Tang
Yuqi Tang
SWShuang Wang
Shuang Wang
SLShutong Liu
Shutong Liu
CLChenglin Li
Chenglin Li
LLLing Li
Ling Li
Background Cyclin B (CCNB) family plays key roles in the cell cycle, cell division and proliferation. Three members of CCNB family have been identified, including CCNB1, CCNB2 and CCNB3. Many studies have explored the roles of CCNBs in the tumorigenesis and pathogenesis of different types of cancer. However, the expression level, function, and prognostic value of CCNBs in breast caner (BC) are still unclear.Methods We explored the specific alterations of CCNBs in BC and predicted their prognostic value for BC patients. Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), Kaplan-Meier plotter, cBioPortal, STRING, Database for Annotation,Visualization and Integrated Discovery (DAVID) databases were used for above analyses.Results We found that CCNB1 amd CCNB2 were significantly overexpressed in BC compared with normal samples, but not CCNB3. Survival analysis showed that upregulated CCNB1 and CCNB2 expression levels were associated with poor prognosis of BC patients, while high CCNB3 expression was related to good prognosis for BC patients. Furthermore, gene oncology (GO) enrichment analysis was performed to reveal the functions of CCNBs and the interacted genes related to CCNBs. In addition, hsa-miR-139-5p and has-miR-944 were identified to be potentially involved in the regulation of CCNB1.Conclusion Our study suggests that CCNB1, CCNB2 are potential targets of precise therapy for BC patients and that CCNB3 is a novel biomarker for the good prognosis of BC patients.

1 July 2025 in BMJ Neurology Open
Verified
Journal Article
Open access
PDF file
YTYuqi Tang
Yuqi Tang
ZQZhandong Qiu
Zhandong Qiu
YDYingyue Ding
Yingyue Ding
ZLZheng Liu
Zheng Liu
HDHuiqing Dong
Huiqing Dong
DLDawei Li
Dawei Li
Background: Tumefactive demyelinating lesions (TDLs) are rare, large demyelinating lesions of the central nervous system that can mimic brain tumours in radiological appearance. They have been observed across multiple demyelinating diseases. Previous studies have suggested that antibody profiles may correlate with distinct clinical or imaging characteristics, but detailed comparisons between antibody-defined subgroups in TDLs remain limited. Methods: We retrospectively analysed 30 patients with confirmed TDLs. Demographic, clinical, imaging and laboratory data were collected, and patients were stratified by myelin oligodendrocyte glycoprotein (MOG) and N-methyl-D-aspartic acid receptor (NMDAR) antibody results. Lesion characteristics were evaluated on brain MRI, and outcomes were assessed by modified Rankin Scale at last follow-up. Statistical comparisons were made between antibody-positive and antibody-negative subgroups. Results: Among TDLs subgroups, MOG+ patients had elevated cerebrospinal fluid white cell counts and showed greater lesion volume reduction on follow-up MRI than MOG− patients. NMDAR+ patients showed elevated levels of systemic inflammatory markers compared with NMDAR− counterparts. Regardless of antibody status, most TDLs patients responded well to immunotherapy, with 86.7% achieving a favourable outcome. Conclusions: TDLs represent a heterogeneous inflammatory syndrome. MOG and NMDAR antibodies influence the clinical and laboratory characteristics of TDL patients but have limited impact on prognosis.